High-dose Wegovy leads to substantial weight loss in trial

Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.
Novo Suffers Wegovy Trial Setback as US Plans to Cut Price
Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed more pounds in a trial than a standard dosage.
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. | In the phase 3b STEP UP study,
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
New dementia cases in US projected to double to 1 million by 2060: Study
A new study found that dementia cases in the United States are projected to double from more than 500,000 in 2020 to about 1 million by 2050.
Wider benefits of Ozempic, Wegovy put pressure on Canadian insurers to expand drug coverage
Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...
Benefits Pro11d
Will Wegovy help that worker lose weight?
New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.
NJBIZ11d
GLP-1 users spend less at the supermarket, Cornell study finds
As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...